Protagonist Therapeutics (PTGX) Gets a Buy from Truist Financial

In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Protagonist Therapeutics. The company’s shares closed last Friday at $87.00.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

According to TipRanks, Devarakonda is a 4-star analyst with an average return of 10.2% and a 49.20% success rate. Devarakonda covers the Healthcare sector, focusing on stocks such as Scholar Rock Holding, Eli Lilly & Co, and Protagonist Therapeutics.

Protagonist Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $72.80, a -16.32% downside from current levels. In a report released on October 10, Wedbush also maintained a Buy rating on the stock with a $70.00 price target.

PTGX market cap is currently $5.41B and has a P/E ratio of 122.09.

Based on the recent corporate insider activity of 38 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PTGX in relation to earlier this year. Most recently, in July 2025, DINESH V PH D PATEL, the President & CEO of PTGX sold 10,415.00 shares for a total of $570,533.70.